Isomorphic Labs Seeks Funding at Valuation of $40 Billion
THE SO WHAT
A $40B valuation target for Isomorphic Labs puts AI-native drug discovery into megacap territory—capital markets are treating model + wet lab integration as a new pharma stack, not a tool. If you’re in life sciences, assume your counterparties will increasingly be AI-first platforms with leverage over target selection and IP.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureAvaada Electro Said to Plan $786 Million India IPO in November
Avaada Electro’s planned $786M IPO underscores how solar manufacturing is becoming a capital-intensive, domestic priority in India’s energy strategy. Infra-heavy AI builders should be watching these markets—the cheapest, cleanest power over the next decade may come from regions scaling solar and storage fastest.
Startups & VentureExclusive: Weight loss startup Yazen raises €50m led by Verdane
Consumer health is still one of the few categories where narrative plus outcomes can justify late-stage checks. If you’re building in digital health, assume investors will demand either clear reimbursement pathways or subscription economics that look more like SaaS than coaching.
Startups & VentureBending Spoons CEO on why M&A fails
The failure mode in most acquihires and rollups is integration discipline, not deal logic. If you’re buying product or talent this cycle, over-allocate leadership time to post-close operating cadence and under-allocate to pre-close pitch theater.
Startups & VentureWhy Investors Are Skeptical Over Australian Data Center Company Firmus's IPO
A polarizing IPO for an Nvidia-backed data center builder shows public markets are starting to separate “AI infra beta” from real contracted demand. If you’re raising for infra-heavy AI plays, expect sharper questions on utilization, power contracts, and tenant concentration — not just logo slides and Nvidia proximity.